Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a leader in the development of differentiated targeted radiotherapies, announced today that new preclinical data for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback